English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/153913
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases

AuthorsBorroto Revuelta, Aldo ; Reyes-Garau, Diana; Jiménez, M. Angeles ; Carrasco, Esther ; Moreno, Beatriz; Martínez-Pasamar, Sara; Cortés, José R.; Perona, Almudena ; Abia, David ; Blanco, Soledad; Fuentes, Manuel ; Arellano Rojo, Irene; Lobo, Juan; Heidarieh, Haleh; Rueda, Javier ; Esteve, Pilar ; Cibrián, Danay; Martínez-Riaño, Ana; Mendoza, Pilar; Prieto, Cristina ; Calleja, Enrique; Oeste, Clara L. ; Orfao, Alberto ; Fresno, Manuel ; Sánchez-Madrid, Francisco; Alcamí, Antonio ; Bovolenta, Paola ; Martín, Pilar; Villoslada, Pablo; Morreale, Antonio ; Messeguer, Ángel; Alarcón, Balbino
Issue Date2016
CitationScience Translational Medicine 8 (2016)
AbstractModulating T cell activation is critical for treating autoimmune diseases but requires avoiding concomitant opportunistic infections. Antigen binding to the T cell receptor (TCR) triggers the recruitment of the cytosolic adaptor protein Nck to a proline-rich sequence in the cytoplasmic tail of the TCR's CD3e subunit. Through virtual screening and using combinatorial chemistry, we have generated an orally available, low-molecular weight inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activationwith an IC50 (median inhibitory concentration) ~1 nM. By modulating TCR signaling, the inhibitor prevented the development of psoriasis and asthma and, furthermore, exerted a long-lasting therapeutic effect in a model of autoimmune encephalomyelitis. However, it did not prevent the generation of a protective memory response against amouse pathogen, suggesting that the compound might not exert its effects through immunosuppression. These results suggest that inhibiting an immediate TCR signal has promise for treating a broad spectrumof human T cell-mediated autoimmune and inflammatory diseases.
Identifiersdoi: 10.1126/scitranslmed.aaf2140
issn: 1946-6242
Appears in Collections:(IQFR) Artículos
(CBM) Artículos
(IQAC) Artículos
(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.